<DOC>
	<DOCNO>NCT01981187</DOCNO>
	<brief_summary>The purpose signal seek study determine whether treatment LGX818 demonstrate sufficient efficacy select pathway-activated solid tumor and/or hematologic malignancy warrant study</brief_summary>
	<brief_title>LGX818 Patients With BRAFV600 Mutated Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Patient confirm diagnosis select solid tumor ( except primary diagnosis melanoma colorectal cancer ( CRC ) ) hematologic malignancy need treatment progression relapse . Patient 's tumor evaluate preidentified tumor BRAFV600 mutation CLIA certify laboratory . Patient must receive least one prior treatment recurrent , metastatic /or locally advance disease standard therapy option anticipate result durable remission . Patient must progressive measurable disease per RECIST 1.1. appropriate hematological response criterion . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Patient receive prior treatment LGX818 . Patients Central Nerve System ( CNS ) metastasis leptomeningeal carcinomatosis . Patient receive chemotherapy anticancer therapy ≤ 4 week ( 6 week nitrosourea , antibody mitomycinC ) prior start study drug . Patients acute chronic pancreatitis . Patients impaired cardiac function clinically significant cardiac disease . Patients another primary malignancy within 3 year prior start study treatment , exception adequately treat basal cell carcinoma , squamous cell carcinoma nonmelanomatous skin cancer , insitu carcinoma uterine cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>